Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Travere Therapeutics Inc shares valued at $221,258 were sold by Calvin Sandra on Nov 25 ’24. At $18.30 per share, Calvin Sandra sold 12,090 shares. The insider’s holdings dropped to 54,927 shares worth approximately $1.07 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Calvin Sandra purchased 12,090 shares, netting a total of over 221,258 in proceeds.
Before that, LYONS GARY A had sold 40,000 shares from its account. In a trade valued at $589,101, the Director traded Travere Therapeutics Inc shares for $14.73 each. Upon closing the transaction, the insider’s holdings decreased to 40,000 shares, worth approximately $0.99 million.
As published in a research note from Wells Fargo on October 21, 2024, Travere Therapeutics Inc [TVTX] has been rated up from an Equal weight to an Overweight and the price target has been revised to $27 from $9. Analysts at Scotiabank started covering the stock with ‘”a Sector outperform”‘ outlook in a report released in mid October. As of September 09, 2024, Guggenheim has increased its “Neutral” rating to a “Buy” for TVTX. Earlier on March 27, 2024, Guggenheim downgraded its rating. Their new recommendation was “a Neutral” for TVTX stock which previously was a “a Buy”.
Analyzing TVTX Stock Performance
During the last five days, there has been a surge of approximately 3.80%. Over the course of the year, Travere Therapeutics Inc shares have jumped approximately 115.91%. Shares of the company reached a 52-week high of $20.33 on 11/11/24 and a 52-week low of $5.12 on 04/25/24. A 50-day SMA is recorded $17.48, while a 200-day SMA reached $10.64. Nevertheless, trading volume fell to 0.56 million shares from 97188.0 shares the previous day.
Support And Resistance Levels for Travere Therapeutics Inc (TVTX)
According to the 24-hour chart, there is a support level at 19.16, which, if violated, would cause prices to drop to 18.91. In the upper region, resistance lies at 19.63. The next price resistance is at 19.85. RSI (Relative Strength Index) is 62.09 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.86, which suggests the price will decrease in the coming days. Percent R is at 18.53%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
